GlaxoSmithKline goes one for two in Indian patent challenges
Section 3(d) was at issue in both cases, but the discussions about section 8 reporting requirements may be of particular importance to patentees
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: